SCHEMBL476675

SCHEMBL476675

Cc1cc2ccc(Cl)c(Cl)c2n1CCCNS(=O)(=O)N(C)C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
CYP2D6 P10635 2/20 0.33
USP2 O75604 1/20 0.33
ESR1 P03372 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CASP1 P29466 1/20 0.33
CYP2C19 P33261 1/20 0.33
HTR6 P50406 2/20 0.32
POLB P06746 2/20 0.32
MAPT P10636 2/20 0.32
FGB P02675 1/20 0.32
KDM4E B2RXH2 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
ALDH1A1 P00352 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL476619 0.87 ALDH1A1 (0.39) HTTKMT2AMEN1CYP2D6USP2
SCHEMBL5675132 0.79 MEN1 (0.44) HTTKMT2AMEN1CYP2D6USP2
SCHEMBL5673232 0.76 HTR2A (0.35) GAAKMT2AMEN1MAPTKDM4E
SCHEMBL476604 0.72 RECQL (0.41) LMNAHTTKMT2AMEN1CYP2D6
SCHEMBL20504942 0.71 HTR2A (0.36) ALDH1A1HTR2AHTR2C
SCHEMBL476711 0.69 PTGS1 (0.39) HTTKMT2AMEN1CYP2D6USP2
SCHEMBL476594 0.68 ALDH1A1 (0.37) KMT2AMEN1CYP2D6USP2ESR1
SCHEMBL476637 0.68 ALDH1A1 (0.39) HTTKMT2AMEN1CYP2D6USP2
SCHEMBL20505256 0.65 CYP1A2 (0.34) CYP1A2CYP3A4CYP2C19ALDH1A1TSHR
SCHEMBL476538 0.65 SMN1; SMN2 (0.40) LMNAHTTKMT2AMEN1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951225-B1 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-02-01 EP disclosed
US-7741363-B2 3-Acylindole derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-06-22 US disclosed
US-20080275102-A1 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275102-A1 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF F12, ECI1, NQO2 LMNA 1750/4885HTT 1044/4885GAA 951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.